Anticoagulants after Discharge in Patients with COVID-19: What we Know at the End of 2021
Open Access
- 11 January 2022
- journal article
- research article
- Published by Silicea - Poligraf in Rational Pharmacotherapy in Cardiology
- Vol. 17 (6), 908-915
- https://doi.org/10.20996/1819-6446-2021-12-07
Abstract
This review discusses reasons for prolonged use of anticoagulants after discharge of patients with COVID-19 without additional indication for anticoagulation. Data regarding rate of thrombotic and thromboembolic complications in patients with COVID-19 after discharge from the hospital are presented. Large randomized controlled trials EXCLAIM, ADOPT, MAGELLAN, APEX and MARINER with prolonged use of anticoagulants in patients hospitalized with acute nonsurgical diseases before pandemia of COVID-19 are discussed. The first prospective randomized controlled trial MICHELLE with direct oral anticoagulant rivaroxaban in a dose 10 mg once daily after discharge of patients with COVID-19 with high risk at least venous thromboembolism are analyzed. It seems that the most relevant approach for the determination of indications for prolonged use of anticoagulants in doses dedicated for primary prevention of venous thromboembolism after discharge of patients with COVID-19 without apparent indication for anticoagulation is a modified IMPROVE VTE risk score with the addition of elevated in-hospital D-dimer level. And the most well-studied approach for anticoagulation in these patients is a direct peroral anticoagulant rivaroxaban 10 mg once daily for 35 (and possibly up to 45) days after discharge.Keywords
This publication has 17 references indexed in Scilit:
- Incidence of thrombotic outcomes for patients hospitalized and discharged after COVID-19 infectionThrombosis Research, 2020
- Postdischarge thrombosis and hemorrhage in patients with COVID-19Blood, 2020
- Postdischarge venous thromboembolism following hospital admission with COVID-19Blood, 2020
- Post-Discharge Prophylaxis With Rivaroxaban Reduces Fatal and Major Thromboembolic Events in Medically Ill PatientsJournal of Invasive Cardiology, 2020
- Rivaroxaban for Thromboprophylaxis after Hospitalization for Medical IllnessThe New England Journal of Medicine, 2018
- Extended Thromboprophylaxis with Betrixaban in Acutely Ill Medical PatientsThe New England Journal of Medicine, 2016
- Rivaroxaban for Thromboprophylaxis in Acutely Ill Medical PatientsThe New England Journal of Medicine, 2013
- Apixaban versus Enoxaparin for Thromboprophylaxis in Medically Ill PatientsThe New England Journal of Medicine, 2011
- Extended-Duration Venous Thromboembolism Prophylaxis in Acutely Ill Medical Patients With Recently Reduced MobilityAnnals of Internal Medicine, 2010
- Extended-duration thromboprophylaxis in acutely ill medical patients with recent reduced mobility: Methodology for the EXCLAIM studyJournal of Thrombosis and Thrombolysis, 2006